Analysts Set Expectations for TNYA Q1 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at Lifesci Capital issued their Q1 2026 earnings per share (EPS) estimates for Tenaya Therapeutics in a note issued to investors on Thursday, March 12th. Lifesci Capital analyst T. Pardo-Garcia expects that the company will earn ($0.14) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.59) EPS.

TNYA has been the topic of a number of other reports. HC Wainwright lowered their target price on Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Canaccord Genuity Group cut their price target on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Chardan Capital reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Tenaya Therapeutics in a research note on Thursday. Leerink Partners reiterated an “outperform” rating and issued a $2.00 target price on shares of Tenaya Therapeutics in a report on Thursday. Finally, Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Tenaya Therapeutics Stock Down 4.5%

Shares of Tenaya Therapeutics stock opened at $0.85 on Friday. The business has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $1.12. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.35. The firm has a market cap of $139.57 million, a price-to-earnings ratio of -1.37 and a beta of 3.22.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Wednesday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12).

Insider Activity at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $0.56, for a total value of $1,966,622.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 8,594,047 shares of company stock worth $5,430,207 over the last three months. Corporate insiders own 48.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Savant Capital LLC purchased a new stake in shares of Tenaya Therapeutics in the 2nd quarter valued at approximately $52,000. Corient Private Wealth LLC acquired a new position in Tenaya Therapeutics in the 4th quarter worth approximately $72,000. Cerity Partners LLC grew its position in Tenaya Therapeutics by 403.5% during the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after purchasing an additional 88,424 shares in the last quarter. Comerica Bank acquired a new stake in Tenaya Therapeutics during the 1st quarter valued at $50,000. Finally, Scientech Research LLC acquired a new stake in Tenaya Therapeutics during the 3rd quarter valued at $27,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.